TAIPEI , Nov. 17, 2020. Medigen Vaccine Biologics Corp. ("MVC") (TPEx: 6547), a global biopharmaceutical company focused on the development of innovative vaccines, has successfully complete the closing of total 1.92 Billion TWD (67.27 million USD) follow-on public offering of 24,000,000 shares of common stock at a price of $80 TWD per share.